Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: Nested cohort crossover study

Lancet

Volumn 358, Issue 9287, 2001, Pages 1042-1045

  Marcil, Isabelle ^a   Stern, Robert S ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; PSORALEN;

ADULT; ARTICLE; CANCER RISK; CLINICAL TRIAL; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DRUG EFFICACY; DRUG EXPOSURE; FEMALE; FOLLOW UP; FREQUENCY ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PSORIASIS; PUVA; RADIATION EXPOSURE; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA;

EID: 0035968626     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(01)06179-7     Document Type: Article

References (22)

1. Risk of neoplasia in renal transplant patients
2. Clinical risk factors associated with nonmelanoma skin cancer in renal transplant recipients
3. Cancer risk after renal transplantation in the Nordic Countries, 1964-1986
4. Incidence of skin cancer in 5356 patients following organ transplantation
5. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens
6. The risk of skin cancer in renal transplant recipients in Queensland, Australia: A follow-up study
7. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of non-melanoma skin cancer: PUVA Follow-Up Study
8. PUVA and cancer: A large scale epidemiological study
9. Skin tumors in the European PUVA Study: Eight-year follow-up of 1,643 patients treated with PUVA for psoriasis
10. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells
11. Successful treatment of severe psoriasis with basiliximab, an interleukin-2 receptor monoclonal antibody
12. Treatment of chronic plaque-stage psoriasis and psoriatic arthritis with mycophenolate mofetil
13. Multiple squamous-cell carcinomas in a psoriatic patient following high-dose photochemotherapy and cyclosporin treatment: Response to long-term acitretin maintenance
14. Risk of cutaneous carcinoma in patients treated with oral methoxsalen photochemotherapy for psoriasis
15. Cutaneous squamous-cell carcinoma in patients treated with PUVA
16. Differentiating squamous cell carcinoma from keratoacanthoma using histopathological criteria: Is it possible? A study of 296 cases
17. The carcinogenic risk of treatments for severe psoriasis
18. Intermittent short courses of cyclosporin (Neoral for psoriasis unresponsive to topical therapy: A 1-year multicentre, randomized study
19. A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral, and Sandimmune, in patients with severe psoriasis
20. Cyclosporine induces cancer progression by a cell-autonomous mechanism
21. A transformed view of cyclosporine